What's new in HIV/AIDS. Protective immunity in HIV infection: where do we stand?
In the face of a global epidemic of HIV/AIDS with the majority of individuals living in the developing countries, a protective vaccine seem the foremost goal. As this is not within imminent reach, the other option would be immunotherapy that prolongs the asymptomatic phase of infection. The basis for such a therapy is to understand the correlates of protective immunity against HIV. Here we present the most recent advances regarding selected parts of the immune response towards HIV.
Draenert
R
R
Dept. of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, D-80336, Munich, Germany.
Goebel
F-D
FD
D016915:AIDS Vaccines; D000917:Antibody Formation; D000956:Antigens, Viral; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003713:Dendritic Cells; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D016915:AIDS Vaccines; D000956:Antigens, Viral